ENDOMETRIAL HYPERPLASIA – WHAT IS NEW?
Journal Title: Journal of Evidence Based Medicine and Healthcare - Year 2014, Vol 1, Issue 11
Abstract
The diagnosis and classification of endometrial hyperplasia is still one of the rare areas in histopathology that is still purely based on morphology without the use of ancillary techniques. The two popular systems used for classification of endometrial hyperplasia are the WHO system and the newer still not so popular EIN system proposed by the Endometrial Collaborative Group. Herein we discuss these two systems of classification and the implications for management of patients thus classified with emphasis on pitfalls in the assessment of follow up biopsies of patients managed conservatively.
Authors and Affiliations
Halamandge Vijay, Rajesh Para
Keywords
Related Articles
- EP ID EP225928
- DOI 10.18410/jebmh/2014/217
- Views 73
- Downloads 0
ESTIMATION OF STATURE BASED ON FOOT LENGTH
BACKGROUND: Stature is the height of the person in the upright posture. It is an important measure of physical identity. Estimation of body height from its segments or dismember parts has important considerations for ide...
A CASE REPORT ON ENLARGED THYMUS IN ADULT HUMAN CADAVER
An unusually enlarged Thymus is seen in superio anterior mediastinum interspersed between aorta and superior vena cava, observed in adult male cadaver during routine dissection. This finding could be mistaken as intrathy...
HYPOTHYROIDISM AND AGEING EFFECT ON PULMONARY ARTERY SYSTOLIC PRESSURE
BACKGROUND Hypothyroidism is a cause of pulmonary artery hypertension. Increased BMI also contributes to pulmonary artery hypertension. Increasing age in healthy people is associated with increasing pulmonary artery pres...
AN AUDIT OF MATERNAL DEATHS
OBJECTIVES: A study of maternal death conducted to evaluate various factors responsible for maternal deaths. To identify complications in pregnancy, a childbirth which result in maternal death, and to identify opportunit...
EFFICACY OF CANAGLIFLOZIN AS AN ADD-ON TO TRIPLE DRUG TREATMENT WITH GLIMEPIRIDE, METFORMIN AND TENELIGLIPTIN
BACKGROUND Canagliflozin is a well-tolerated sodium-glucose transporter 2 inhibitor, with remarkable efficacy in providing glycaemic control in patients with type 2 diabetes mellitus (T2DM). However, limited evidence is...